Response
We welcome the interest of Dr Chen-Scarabelli et al in our article. 1 They state, correctly, that release of cardiac troponin I (cTnI) after on-pump cardiac surgery does not necessarily imply irreversible myocardial injury. Indeed, as discussed in our article, this was a fundamental rationale for using cardiac magnetic resonance imaging to distinguish between reversible and irreversible myocardial injury in our randomized trial of on-and off-pump surgery. We previously reported in a series of 150 patients that the predominantly early pattern of cTnI release after on-pump cardiac surgery, with peak values observed within 6 to 12 hours after cardiopulmonary bypass, was inconsistent with true myocardial necrosis (in which case peak levels would not be seen for 48 to 72 hours) but was more likely to represent a cytoplasmic "washout" phenomenon. 2 This phenomenon is likely to be exaggerated in onpump surgery because of the increased cell wall permeability that accompanies the systemic inflammatory response of cardiopulmonary bypass 3 and is, by far, the most likely explanation for the higher cTnI levels reported early after on-pump surgery by Khan and colleagues. 4 The suggestion by Dr Chen-Scarabelli et al that "an earlier and greater release of cTnI in on-pump surgery patients should be paradoxically welcomed as a marker of earlier and greater reperfusion" is not only counterintuitive but potentially harmful in the setting of coronary artery surgery, where strenuous efforts are made to minimize cardiac ischemia. Elevation of cardiac enzymes is already known to be associated with both a higher mortality rate and a significantly increased risk of subsequent adverse cardiac events after percutaneous coronary intervention, and more recently, a 5-fold increase in creatine kinase-MB early after coronary artery bypass surgery was reported to be associated with a significantly greater 1-year risk of death and myocardial infarction. 5 
